Evidence-Based Acupuncture and Herbal Medicine for Breast Cancer
Zuobiao Yuan has 30+ years of experience using acupuncture and Chinese Medicine to help with cancer and other complicated disorders. He is the owner of Yi Acupuncture & Chinese Medicine.
This guide was prepared for clinic patients by Dr. Zuobiao Yuan. He completed a bachelor’s degree in traditional Chinese medicine in Jiangxi in 1993 and a PhD at Shanghai University of Traditional Chinese Medicine in 2000, under Professor Zhu Peiting at Longhua Hospital. He has been a specially appointed professor at Shanghai universities since 2012.
He later conducted research related to pancreatic cancer and pancreatitis in the Department of Surgery at the University of Minnesota and taught internal medicine, reproductive disorders, and oncology in master’s and doctoral programs at the American Academy of Acupuncture and Oriental Medicine. With more than thirty years in practice, a substantial part of his clinical work has been supportive care for people with cancer and chronic illness. Yi Acupuncture & Chinese Medicine, in Woodbury, Minnesota, sees many patients who are receiving or have completed oncology treatment and want help with treatment-related symptoms.
The background is included so readers know the text comes from a licensed acupuncturist with oncology-related training and long clinical observation, not from an internet remedy list. It does not change the standing of this article. In this clinic, acupuncture and herbs remain adjuncts to oncology care. They do not replace surgery, radiation, or systemic therapy, and a résumé is not a promise of outcome.
What is breast cancer?
Breast cancer is a group of malignant tumors that arise from ductal or lobular epithelium. It is the most commonly diagnosed cancer in women worldwide. It is not one disease. Hormone receptor status, estrogen receptor (ER) and progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, and grade divide tumors into hormone receptor positive, HER2 positive, triple negative, and finer molecular subtypes. Stage ranges from in situ disease to early invasive cancer, locally advanced disease, and distant metastasis. Treatment pathways differ accordingly.
Modern care combines, as indicated, breast-conserving surgery or mastectomy with sentinel node or axillary surgery, radiation, chemotherapy, including anthracyclines, taxanes, platinum agents, and others, endocrine therapy, including tamoxifen, aromatase inhibitors, and ovarian suppression, often for 5 to 10 years, anti-HER2 therapy, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, antibody drug conjugates, and immunotherapy. Delaying these modalities in favor of “constitution-only” care can cost a curative window.
Treatment also has a cost, nausea, marrow suppression, and peripheral neuropathy after chemotherapy, hot flashes, arthralgia, vaginal dryness, and bone loss on endocrine therapy, lymphedema risk after axillary surgery, radiation skin injury, cancer-related fatigue, insomnia, anxiety, depression, and “brain fog.” In that setting, acupuncture and herbal medicine are adjuncts, not a separate cure path. Needles and decoctions cannot replace anti-cancer regimens.
How traditional Chinese medicine (TCM) views breast cancer
In classical terms, the disease is often discussed as “breast rock” (ru yan), with patterns of liver qi stagnation, phlegm and blood stasis, Chong Ren disharmony, and deficiency with residual toxin. Two people with the same receptor subtype can look very different, one tight-chested and irritable, another exhausted with poor appetite after chemotherapy, another flushed and aching on an aromatase inhibitor. Prescriptions and point choices are therefore individualized. That difference is one reason supervised care is safer than buying a single “anti-cancer tonic” off a shelf.
For hormone receptor positive disease, an extra question matters. Does the formula contain herbs with possible phytoestrogen activity or cytochrome P450 (CYP) enzyme effects, such as high-dose Angelica, Dang Gui, licorice, Epimedium, and similar items? The product name is not a safety certificate.
Possible advantages of acupuncture
Acupuncture stimulates selected points to influence neural, endocrine, immune, and circulatory pathways. In integrative oncology, the practical interest is not “melting the mass,” but easing treatment-related symptoms so that surgery, radiation, chemotherapy, and years of endocrine therapy can be completed. For patients, the more practical questions are about comfort, function, and safety.
Signals for endocrine therapy related hot flashes: Hot flashes are a leading reason women stop tamoxifen or an aromatase inhibitor. A 2024 pooled individual patient analysis of three parallel randomized trials in the United States, China, and South Korea, involving 158 people on endocrine therapy, found that immediate acupuncture improved hot flash scores, endocrine symptom scores, and breast cancer specific quality of life at week 10 compared with delayed acupuncture. Systematic reviews in 2025, pooling about 11 trials and roughly 900 to 1,000 participants, reported improvement on hot flash symptom scales. Effects on flash frequency were less consistent, and certainty was low to moderate because of bias and heterogeneity. The findings are cautious, but they support a conversation about adding acupuncture to, not instead of, endocrine therapy.
Help with aromatase inhibitor related joint pain: Aromatase inhibitor arthralgia often threatens adherence. A 2025 review of seven randomized trials, involving 604 patients, found better Brief Pain Inventory scores for worst pain, interference, and severity over about six weeks versus sham needling or usual medication, without serious adverse events. American Society of Clinical Oncology (ASCO) and Society for Integrative Oncology (SIO) integrative summaries list acupuncture among non-drug options for this problem.
Support for chemotherapy neuropathy, nausea, and fatigue: Taxanes, platinum agents, and some newer cytotoxics cause numbness and burning. Reviews from 2025 and 2026 focused on breast cancer chemotherapy-induced peripheral neuropathy (CIPN), involving about 10 trials and 650 patients, reported better clinical response and pain scores with acupuncture. Nerve conduction changes were less clear. Broader CIPN reviews in mixed cancers show similar trends. For chemotherapy-induced nausea and vomiting, recent meta-analyses suggest a benefit mainly for delayed vomiting. Acupuncture does not replace guideline antiemetics. Signals also exist for cancer-related fatigue, insomnia, and some cognitive complaints, again with limited certainty.
Safety is generally favorable, with oncology-specific caveats: Included acupuncture trials generally did not report serious needle-related events. Brief ache or a small bruise is more typical when treatment is delivered by a licensed clinician with clean technique. Extra caution is needed in neutropenia, due to infection risk, thrombocytopenia, due to bleeding risk, the at-risk arm after axillary surgery or with lymphedema, open radiation skin, ports, and reconstructed breasts. Points often chosen include Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6), Taichong (LR3), Hegu (LI4), Baihui (GV20), and Shenmen (HT7), plus local points for joint pain, individualized by phase of care. A common course is one to three sessions a week for several weeks to about three months, then review.
Possible advantages of Chinese herbal medicine
Herbal research in breast cancer is abundant but uneven. Most randomized trials are regional and short. International oncology guidelines do not list Chinese herbs as standard anti-tumor therapy. The questions worth discussing are narrower, easing chemotherapy-related digestive symptoms and marrow suppression, helping mood, sleep, and menopause-like symptoms after surgery or endocrine therapy, and quality of life or immune marker changes reported in some hospital-based decoction or herbal injection studies. These remain add-on effects.
Formulas patients hear about in clinic are usually added to, not swapped for, oncology care. Modified Xiaoyao-san has been studied for postoperative depressive symptoms. Spleen-strengthening decoctions, including Liujunzi, Xiangsha Liujunzi, and Huangqi Sijunzi, appear in small trials for fatigue and poor appetite during chemotherapy. Network and pairwise meta-analyses of Chinese herbal injections, for example, Shenqi Fuzheng, plus chemotherapy report trends toward better response rates, less leukopenia, and better performance status, with high heterogeneity and limited generalizability. None of this should be read as “herbs shrink tumors instead of chemotherapy.”
Laboratory work suggests that some constituents affect inflammation, oxidative stress, apoptosis, or resistance pathways. In daily life, a more tangible benefit is that better appetite, sleep, sweating, joint stiffness, or mood can make it easier to stay on the plan you already have. Self-stacked “anti-cancer herbs” of unknown origin can interact with tamoxifen, CDK4/6 inhibitors, anticoagulants, and chemotherapy, and can delay necessary care.
Limitations, drawbacks, and safety warnings
“Natural” is not the same as “harmless,” and “Chinese patent medicine” does not mean “no Western drug and no hormone-like activity inside.” Herbs containing aristolochic acid can cause irreversible kidney injury and raise the risk of urinary tract cancers. These materials are tightly restricted. Unregulated folk recipes and imported “detox/cure breast cancer” products are the riskiest sources. For hormone receptor positive disease, formulas rich in Angelica, licorice, Epimedium, or similar items must be reviewed with oncology before they are used as a daily tonic.
Research is still incomplete: Many herbal trials are small, poorly blinded, short, and mixed in endpoints, so they cannot prove that TCM “cures breast cancer” or reliably cuts recurrence. National Comprehensive Cancer Network (NCCN) materials caution that supplements can interact with systemic therapy. ASCO and SIO recommendations for acupuncture focus on pain, chemotherapy nausea, aromatase inhibitor arthralgia, anxiety, and hot flashes, not on the tumor itself. Experienced clinicians treat current reports as leads, not guarantees.
It cannot replace surgery, systemic therapy, or emergency care: Newly diagnosed operable disease, the neoadjuvant window, febrile neutropenia, suspected visceral crisis, new bone pain or neurologic deficits, wound infection, or thrombosis require modern oncology protocols. A growing mass, peau d’orange, bloody nipple discharge, or new shortness of breath is not a reason to add extra needles first.
Drug herb interaction is the most practical stacked risk: Tamoxifen needs CYP2D6 to form endoxifen. Many targeted agents, CDK4/6 inhibitors, cytotoxics, and antiemetics use CYP3A4 or P-glycoprotein. Berberine, St. John’s wort, high-dose green tea extracts, and high-dose curcumin have reported interaction potential. Blood-moving herbs may affect clotting around surgery or anticoagulation. List every prescription, patent medicine, supplement, and “anti-cancer tea” before any adjunctive plan starts.
Product quality, estrogen-like activity, and organ burden: The same herb name can differ by origin, processing, and dose. Some “kidney-tonifying” or “blood-nourishing” formulas contain phytoestrogen-like constituents whose long-term safety in ER positive disease is not established at high quality. Long-term high-dose licorice may raise blood pressure and lower potassium. Dose and product choice need extra care when the liver or kidneys are impaired or when hepatotoxic chemotherapy is in use.
Acupuncture has practical limits: Bleeding disorders, infected or irradiated skin, pregnancy, pacemakers, if electroacupuncture is planned, and the lymphedema-risk arm must be disclosed. Repeated visits can be hard during recovery. If you feel light-headed after a session, check for anemia, volume depletion, or low glucose before you leave.
How to read “the evidence is still not strong”
When patients hear “low-quality evidence” or “guidelines do not list herbs as anti-cancer therapy,” it is easy to conclude, “it does not work.” A fairer reading is this. There are still too few rigorously designed, adequately long studies of acupuncture and Chinese herbs that use survival or recurrence as primary endpoints and that can separate treatment from placebo, so systematic reviews and international guidelines stay conservative. Symptom evidence is stronger for selected acupuncture indications than for tumor control. A modest evidence grade often means that research on hard oncology outcomes has not caught up with clinical use, not that every clinical observation has been disproved.
Published trials and mechanism papers can still give useful direction, which points, which formulas, and which safety endpoints deserve careful testing next. An experienced Chinese medicine physician does not treat one paper as a fixed anti-cancer prescription. He or she folds those reports into pattern-based practice for the right patient at the right phase of care, while actively steering around delayed standard therapy, hidden interactions, and known organ toxicity, and then adjusts the plan with oncology-scheduled imaging and blood work. For patients, choosing a clinician who reads both the literature and the pathology report matters more than copying a formula from the internet.
How to read tumor changes seen in this clinic
At Yi Acupuncture & Chinese Medicine, most people with breast cancer received pattern-based acupuncture or herbs here while they continued care with a breast surgeon, medical oncologist, or radiation oncologist. In some of those patients, oncology imaging later showed a smaller mass. In a few, consecutive positron emission tomography computed tomography (PET CT) scans showed no cancer activity. Those records come from oncology imaging and/or pathology. They are not a clinic declaration of “tumor clearance” or “cure.”
Three points belong in front of the observation. First, neoadjuvant chemotherapy, anti-HER2 therapy, endocrine therapy, or immunotherapy can themselves shrink a tumor. Some patients reach a pathologic complete response, meaning no residual invasive cancer in the operative specimen. When the same finding appears in someone who also received acupuncture or herbs, that does not prove the needles or the formula caused the change, and it does not move credit away from the oncology plan. Second, these are uncontrolled individual records. They are not a response rate, and they do not predict the next patient’s result. Third, they are not a reason to decline, delay, or stop surgery, radiation, chemotherapy, endocrine therapy, or targeted therapy.
Who may be a reasonable candidate?
People most often considered for adjunctive TCM already have a confirmed diagnosis and stage, are receiving or have completed standard anti-cancer therapy, are stable in oncology follow-up, and are mainly seeking help with hot flashes, aromatase inhibitor joint pain, chemotherapy neuropathy, nausea, cancer-related fatigue, insomnia, or distress, without current febrile neutropenia, active infection, uncontrolled coagulopathy, or severe ipsilateral lymphedema. Newly undiagnosed masses, refusal of indicated oncology care, pregnancy-associated breast cancer, unevaluated suspected recurrence, or new neurologic deficits should be treated as oncology problems first. Please bring pathology and receptor reports, recent imaging and tumor markers, a full medicine list, a complete blood count and chemistry panel, and notes on which side was operated on and whether the arm swells.
Bottom line
Taken together, current clinical research suggests that acupuncture, used as an adjunct, may help some people with breast cancer feel better, especially with endocrine therapy related hot flashes, aromatase inhibitor joint pain, chemotherapy neuropathy, delayed nausea, fatigue, and sleep or mood disruption. Under licensed care that respects neutropenia and the at-risk arm, serious needle-related harm appears uncommon. Chinese herbs have regional research signals for easing selected chemotherapy toxicities and emotional symptoms, but the evidence grade is modest, and interaction, phytoestrogen, and quality concerns are real. International oncology guidelines do not list herbs as standard anti-tumor therapy.
Acupuncture recommendations are mainly for specific symptoms, not for the mass itself. In this clinic, a small number of patients have had imaging shrinkage or no residual invasive cancer on surgical pathology while receiving standard oncology care plus adjunctive TCM. That should be read as an individual event during standard treatment, not as an effect that can be credited to acupuncture or herbs alone or promised to the next patient. Published reports and clinic observations are useful as leads. Experienced Chinese medicine physicians fold them into pattern-based practice while working to avoid delayed standard treatment, hidden interactions, and known organ toxicity. These tools still belong beside modern breast cancer care, with scheduled oncology follow-up and qualified clinicians, never instead of that care.
Read more from Zuobiao Yuan
Zuobiao Yuan, Founder of Yi Acupuncture & Chinese Medicine
Zuobiao Yuan is an expert in acupuncture and Chinese Medicine, in cancer care, and complicated disorders including but not limited to pain, mental health, infertility, kidney/heart/lung dysfunction, and diabetes. He holds a PhD and a specially appointed professor at Shanghai University of Traditional Chinese Medicine, with good research experience at internally recognized universities.
References:
[1] Lu W, Giobbie-Hurder A, Freedman RA, et al. Acupuncture for hot flashes in hormone receptor-positive breast cancer: a pooled analysis of individual patient data from parallel randomized trials. Cancer. 2024;130(18):3219-3228. doi:10.1002/cncr.35374.
[2] How effective is acupuncture in treating hot flashes in breast cancer patients? A systematic review and meta-analysis. Front Oncol. 2025;15:1543938. doi:10.3389/fonc.2025.1543938. PMID: 40165891.
[3] Acupuncture relative to sham control in managing breast cancer-related hot flashes: a meta-analysis of randomized controlled trials. Complement Med Res. 2025;32(5):387-401. doi:10.1159/000547579.
[4] Zhu Z, et al. Effectiveness of acupuncture in managing aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. Acupunct Herb Med. 2025;5(3):352-365.
[5] Efficacy and safety of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis. Front Neurol. 2026;16:1690446. doi:10.3389/fneur.2025.1690446.
[6] The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis. J Cancer Surviv. 2025.
[7] Effectiveness and safety of acupuncture for nausea and vomiting in cancer patients: a systematic review and meta-analysis. Medicina (Kaunas). 2025;61(7):1287.
[8] Efficacy and safety of acupuncture for the treatment of insomnia in breast cancer patients: a systematic review and meta-analysis. Complement Ther Med. 2024;86:103087.
[9] Effects of acupuncture on cancer-related fatigue and quality of life in breast cancer survivors: a systematic review and meta-analysis. Medicine. 2025.
[10] Mao JJ, Ismaila N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology–ASCO guideline. J Clin Oncol. 2022;40(34):3998-4024. (and subsequent ASCO–SIO educational updates through 2025).
[11] Huang B, et al. Efficacy and safety of modified Xiaoyao-san in the treatment of postoperative depression of breast cancer: a systematic review and meta-analysis. Front Pharmacol. 2026;17:1734584.
[12] Traditional Chinese medicine combined with chemotherapy for breast cancer after operation: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(46):e40264. PMID: 39560516.
[13] Shi Y, et al. 8 specific Chinese herbal injections combined with chemotherapy for breast cancer: a systematic review and network meta-analysis. Front Pharmacol. 2025;16:1661803.
[14] Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 2024;24:42.
[15] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version updates 2024–2026; NCCN Guidelines for Patients: Invasive Breast Cancer (supplement/herb interaction cautions).
[16] Yang B, Xie Y, Guo M, Rosner MH, Yang H, Ronco C. Nephrotoxicity and Chinese herbal medicine. Clin J Am Soc Nephrol. 2018;13(10):1605-1611.
[17] Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158-169.
[18] Memorial Sloan Kettering Cancer Center About Herbs. Dang Gui Bu Xue Tang and related monographs (hormone-sensitive cancer cautions; drug–herb interactions).
Disclaimer: This article is for health education. It is not a diagnosis, prescription, or promise of outcome for any individual. Treatment must be planned by licensed clinicians using your pathology, stage, laboratory results, imaging, and other medical conditions. Acupuncture or Chinese herbs must not replace surgery, radiation, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy for breast cancer. Patients with hormone receptor–positive disease should review herbal plans with their oncology team.
